For years I filed M cells under “doorways” and moved on. They are the rare, funny-looking cells studded across the domes of your Peyer’s patches, the immune outposts embedded in the wall of your small intestine, and the textbook job I learned for them is narrow: grab a sample of whatever is drifting through the gut lumen, hand it to the immune cells waiting behind, close the door. Useful, passive, a turnstile with a name. So when a paper in Nature Immunology claimed these turnstiles are actually running the room behind them, I wanted to know what “running” could possibly mean for a cell I had written off as plumbing.

The body's own design is not a flood.

Here is what the Australian team, working in mice, actually found. M cells do not only sample antigen. They organize a physical neighborhood inside the gut wall and use it to house, position, and keep alive a specific squad of immune cells: group 3 innate lymphoid cells, the ILC3s. The whole point of keeping that squad comfortable is a single molecule the ILC3s pour out, IL-22, the cytokine that tells your gut lining to fortify itself and keeps the bacteria sampled inside those Peyer’s patches from breaching the barrier they sit in.

Your Peyer’s patches are deliberately porous. They have to be, because their job is to taste the gut’s bacterial traffic. But an outpost built to let microbes in is an outpost microbes could breach, and IL-22 is what holds that line. The study’s claim is that the M cell is the reason the ILC3s making that IL-22 are there at all.

So how does a doorway become a landlord? The mechanism is so specific it is almost bossy, and that is what made me sit up. The M cells lean on two signals at once. One is a positioning cue, a chemokine gradient the ILC3s follow through their CCR6 receptor, the molecular equivalent of a lit hallway that says stand here, not there. The other is RANK–RANKL signaling delivered straight to the ILC3s, the same RANKL axis that tells an epithelial cell to become an M cell in the first place, now doing double duty as a survival-and-proliferation instruction to the immune cells it hosts. Wait, why would the same molecular conversation that builds the doorway also staff the room behind it? Because it is not two systems. It is one cell type running one program that happens to do both jobs, and once you see that, the elegance is a little unnerving. The niche and its tenants are built by the same hand.

There was a clean control here too, the kind that pins cause to a single cell type. The transcription factor SPI-B is what an epithelial cell needs to become an M cell. The team showed that SPI-B in the epithelium, not in the blood-derived immune cells, was what was required to build this niche and to mount proper intestinal IgA responses. Knock it out where the M cells live and the architecture does not assemble. That is a clean line drawn from which cell to which outcome, and it is why I trust this more than the average mechanism paper.

IL-22 is having a moment, and this study slots into a pattern I have been watching pile up. A 2024 paper in the Journal of Clinical Investigation traced how, in inflammatory bowel disease, the IRE1α/XBP1 stress pathway is what keeps ILC3 cytokine output running, and when it falters the cells go quiet. IL-22 also drives frank tissue repair: a Cell Stem Cell study, funded by Genentech, showed adrenergic nerves steering intestinal regeneration through ILC3-derived IL-22. The reach extends past the gut entirely. An eLife study linked intermittent fasting to more IL-22-secreting ILC3s and, of all things, the beiging of white fat, the metabolically active kind. The same molecule keeps surfacing wherever the body is trying to protect or rebuild a barrier. What this new paper adds is the address: the structure that decides where the IL-22 gets made, and how much.

Let me be straight about what this is and is not. It is mouse work, and the human gut is not a mouse gut. It is mechanism, not medicine: nobody has shown you can walk into a person with a failing barrier and rebuild this niche. And the link between what you eat and this system is anything but simple. If your instinct, like mine, was “so I should push my gut bugs to make more butyrate to feed this,” the data cut the other way: microbiota-derived butyrate has been shown to suppress ILC3s specifically in the terminal ileal Peyer’s patches. More of a good short-chain fatty acid is not automatically more of a good cytokine. The gut does not do linear.

One thing worth naming, because it cuts against the usual grain: this was Australian public and charity money, the NHMRC and the Research Council and Cancer Council NSW, not a drug company building a case for its own molecule. That matters, because IL-22 is already a drug. Genentech, which funded that intestinal-regeneration study, has an IL-22 fusion protein, efmarodocokin alfa, that has run through Phase II trials in ulcerative colitis, dosed straight into the body every four weeks. This new paper is a quiet argument against that whole approach. The body’s own design is not a flood. It is a specific cell building a specific room and delivering a specific instruction to specific tenants in one small district of the gut. Local, organized, addressed.

So this is my decision, not a musing. The systemic IL-22 drugs are not coming; they are here, in trials right now. I would not be an early adopter of anything that dumps this cytokine into my whole body at once. The biology here is telling me the effect is supposed to be built and aimed, not sprayed. I would want a therapy that respects the address, and until one exists, I am keeping my skepticism pointed at any pill that treats a cytokine this architectural as if it were a vitamin.

Sources

  1. Nature Immunology – Peyer’s patch M cells organize an epithelial niche that sustains group 3 innate lymphoid cells and IL-22 (2026)
  2. Journal of Clinical Investigation – The IRE1α/XBP1 pathway sustains cytokine responses of group 3 innate lymphoid cells in inflammatory bowel disease (2024)
  3. Cell Stem Cell – Adrenergic nerves regulate intestinal regeneration through IL-22 signaling from type 3 innate lymphoid cells (2023)
  4. eLife – Intermittent fasting promotes type 3 innate lymphoid cells secreting IL-22, contributing to the beiging of white adipose tissue (2024)
  5. Scientific Reports – Microbiota-derived butyrate suppresses group 3 innate lymphoid cells in terminal ileal Peyer’s patches (2017)
  6. Dose-escalation randomised study of efmarodocokin alfa in healthy volunteers and patients with ulcerative colitis